Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Mira Chalet

Pediatrics Hackensack, NJ Medical Doctor

NPI 1124559497 CMS profile 7504466

177 Summit Ave, Hackensack, NJ 07601

Open in the dashboard

General payments

$1,497

95 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mira Chalet of Hackensack, NJ is reported in the CMS Open Payments database as having received $1,497 across 95 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $308 18
2024 General $349 21
2023 General $399 24
2022 General $184 13
2021 General $210 16
2020 General $46 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mira Chalet
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Mira Chalet were reported at $308. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Mira Chalet Pediatrics median Middle half National median
2019 $0 $86 $31–$183 $163
2020 $46 $49 $22–$110 $114
2021 $210 $68 $27–$158 $132
2022 $184 $77 $30–$173 $149
2023 $399 $88 $33–$190 $160
2024 $349 $94 $34–$206 $164
2025 $308 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. kaleo, Inc. $203 13 payments
  2. Merck Sharp & Dohme Corporation $199 13 payments
  3. GlaxoSmithKline, LLC. $182 11 payments
  4. Sanofi Pasteur Inc. $125 7 payments
  5. Cumberland Pharmaceuticals, Inc. $124 9 payments
  6. Sobi, Inc $113 8 payments
  7. Pfizer Inc. $106 6 payments
  8. AstraZeneca Pharmaceuticals LP $100 5 payments
  9. ARS Pharmaceuticals Operations, Inc. $73 4 payments
  10. Seqirus USA Inc $64 4 payments
  11. Other $208 15 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $1,497 95 payments
Products named General payments · program years 2020–2025
  1. GARDASIL 9 $199 13 payments
  2. BEXSERO $182 11 payments
  3. VAXELIS $166 11 payments
  4. AUVI-Q $166 11 payments
  5. VAXNEUVANCE $157 10 payments
  6. KRISTALOSE $124 9 payments
  7. PEDIARIX $114 7 payments
  8. SYNAGIS $113 8 payments
  9. FLUMIST QUADRIVALENT $100 5 payments
  10. TRUMENBA $89 5 payments
  11. Other $1,144 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record